HIVEP2 Antibodies

Structure of HIVEP2

HIVEP2 is a large-molecular-weight transcription factor, approximately 270 kDa in size. This protein contains multiple zinc finger domains and an acidic activation region, which regulate gene expression by recognizing specific DNA sequences. The molecular weight and structural characteristics of HIVEP2 in different species are as follows:

The HIVEP2 protein contains approximately 2,400 amino acids, and its structure includes multiple zinc finger motifs that form the DNA-binding domain and the acidic region responsible for transcriptional activation. These zinc finger structures can specifically recognize the κB sites in the promoter regions of target genes, thereby regulating the expression of immune-related genes and genes related to neural development. This protein functions in the cell nucleus and participates in important biological processes such as inflammatory responses and neuronal differentiation through interactions with other transcription factors.

Fig. 1 miRNA-186, 210 and 222 directly regulate Dicer1, HRB and HIV-EP21

The key structural characteristics of HIVEP2:

• Multiple zinc finger domains mediate specific recognition of DNA sequences
• Acidic transcriptional activation region regulates downstream gene expression
• Serine-rich region participates in protein interactions
• Nuclear localization signal ensures its localization within the cell nucleus and functional expression

Functions of HIVEP2

The main function of HIVEP2 is to regulate gene expression as a transcription factor, playing a crucial role in immunity and the nervous system.

The DNA binding kinetics of HIVEP2 show that it has high specificity for the κB site, achieving precise regulation of gene expression by recruiting co-activators or inhibitors.

Applications of HIVEP2 and HIVEP2 Antibody in Literature

1. Modai, Shira, et al. "HIV-1 infection increases microRNAs that inhibit Dicer1, HRB and HIV-EP2, thereby reducing viral replication." PloS one 14.1 (2019): e0211111. https://doi.org/10.1371/journal.pone.0211111

The article indicates that after HIV-1 infects Sup-T1 cells, the expressions of miR-186, 210 and 222 increase, thereby inhibiting the host target genes Dicer1, HRB and HIVEP2. These miRNAs can down-regulate viral expression and may play a key role in HIV-1 replication and miRNA generation, providing new ideas for treatment.

2. Zhao, Juan, et al. "Identification of HIVEP2 as a dopaminergic transcription factor related to substance use disorders in rats and humans." Translational Psychiatry 9.1 (2019): 247. https://doi.org/10.1038/s41398-019-0573-8

The research has found that HIVEP2 is a key factor regulating dopamine neurons and can activate the SLC6A3 gene. This mechanism plays a role in substance use disorders and shows gender differences, providing a new perspective for understanding addiction.

3. Abreu, Maria, et al. "Parental gonadossomatic mosaicism in HIVEP2-related intellectual disability and impact on genetic counseling–case report." Frontiers in Genetics 14 (2023): 1156847. https://doi.org/10.3389/fgene.2023.1156847

The study identified a case of autosomal dominant intellectual disability type 43 (MRD43) caused by a HIVEP2 gene mutation. The patient's mother was a healthy mosaic individual, raising the recurrence risk to 50%, highlighting the importance of parental testing in genetic counseling.

4. Murphy, Caitlin E., et al. "Nuclear factor kappa B activation appears weaker in schizophrenia patients with high brain cytokines than in non-schizophrenic controls with high brain cytokines." Journal of Neuroinflammation 17.1 (2020): 215. https://doi.org/10.1186/s12974-020-01890-6

The study found that in patients with schizophrenia accompanied by high neuroinflammation, the expression of HIVEP2 in the prefrontal cortex was decreased, and the transcription of its upstream activation factor NF-κB was weaker than that of the high inflammation control group. This suggests that the absence of HIVEP2 may be related to the weakened regulation of inflammation.

5. Karaoglu, Ismail Can, et al. "Single–gene knockout of RNLS or HIVEP2 are insufficient to protect β–cell spheroids from allo–and xeno–rejection." Frontiers in Immunology 17 (2026): 1759835. https://doi.org/10.3389/fimmu.2026.1759835

The study found that knocking out the RNLS or HIVEP2 genes failed to protect pancreatic β-cell grafts from immune rejection. This indicates that the effect of a single gene editing is limited and that other strategies need to be combined to achieve the goal of transplant therapy for type 1 diabetes.

Creative Biolabs: HIVEP2 Antibodies for Research

Creative Biolabs specializes in the production of high-quality HIVEP2 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom HIVEP2 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our HIVEP2 antibodies, custom preparations, or technical support, contact us at email.